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INTRODUCTION
Chronic kidney disease (CKD) is a common 
condition in the community.1,2 In the UK, 
according to the Quality and Outcomes 
Framework,3 GPs have been incentivised 
to register patients with CKD stages 
3–5 (estimated glomerular filtration 
rate [eGFR] <60 mL/min/1.73 m2 for 
≥3 months) since 2006. The majority of 
these patients are in CKD stage 3 (eGFR 
of 30–59 mL/ min/1.73 m2) and managed 
by GPs without referral to nephrology 
services.4 
There have been concerns, particularly 
among GPs, regarding potential 
overdiagnosis of CKD in older patients with 
mildly reduced kidney function.5,6 Some 
have argued that labelling people as having 
CKD may unnecessarily create anxiety, 
while only a minority of patients with CKD 
progress to end-stage kidney disease 
requiring renal replacement therapy.7,8 
However, patients with CKD are at higher 
risk of cardiovascular events, death, and 
all-cause hospitalisation,9 an important 
outcome for both patients and the national 
healthcare system.10 Awareness of the 
causes of admission among patients with 
CKD could offer opportunities for prevention. 
However, previous studies suggesting a 
positive association between CKD and 
hospitalisations have not investigated the 
specific causes in detail.11–13 
Accumulating evidence suggests that 
CKD is causally associated with a wide 
range of adverse outcomes, including 
acute kidney injury (AKI),14 cardiovascular 
(myocardial infarction,15,16 heart failure,17,18 
and stroke19,20) and non-cardiovascular 
conditions (infection,21,22 bleeding,23,24 venous 
thromboembolism,25,26 and fracture27,28). 
However, to the researchers’ knowledge, 
there has been no study examining the 
extent to which these conditions explain the 
increased risk of all-cause hospitalisation 
in patients with CKD. Identification of more 
common and specific causes of admission 
among patients with CKD is warranted to 
reaffirm the importance of identifying CKD 
in primary care and guide areas of focus for 
outpatient management of these patients.
Therefore, this study aimed to quantify 
the association between CKD and cause-
specific hospitalisation, using a primary 
care database linked to hospital admission 
data. The main purpose of the study was 
to estimate and rank the size of absolute 
risk difference and relative risk between 
patients with and without CKD (matched for 
age, sex, GP, and calendar time) across 10 
common causes of hospital admission.
METHOD 
Data sources
The Clinical Practice Research Datalink 
(CPRD) is a database of routinely recorded 
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primary care electronic health record data.29 
The database represents around 7% of the 
UK population and includes the following 
information: patient demographics; coded 
diagnoses (Read Codes); prescriptions; 
laboratory test results; and referrals made 
by GPs. The CPRD can be linked with 
Hospital Episode Statistics (HES), which 
contains details of all hospital admissions 
at NHS hospitals in England and consists of 
main and subsidiary diagnoses, using the 
10th revision of International Classification 
of Disease (ICD-10) codes.30 Currently 
around 400 GPs in CPRD have consented 
to linkage with HES, representing 75% of 
English practices in CPRD.29 
Study population and matched cohort
All adults in HES-linked CPRD from 1 April 
2004 to 31 March 2014 were potentially 
eligible for inclusion. Patients were eligible 
for inclusion at the latest of: 1 year after 
practice registration,31 the date that the 
GP reached CPRD quality standards,29 
and 1 April 2004. Patients already on renal 
replacement therapy (haemodialysis, 
peritoneal dialysis, or kidney transplantation) 
at cohort entry were excluded. 
First, patients with CKD (stages 
3–5) were identified, defined as two 
consecutive measurements of eGFR 
<60 ml/ min/1.73 m2 for ≥3 months.32 
Estimated GFR was calculated from 
serum creatinine records in CPRD (after 
multiplication of 0.95 to allow for lack of 
creatinine calibration33) using the Chronic 
Kidney Disease Epidemiology Collaboration 
equation.34 Patients, including those who 
had CKD before April 2004, were included 
in the cohort on the date when they first 
satisfied the CKD definition (second eGFR 
<60 mL/min/1.73 m2) after their eligibility. 
Second, for a comparison group, patients 
without known CKD were randomly selected 
from the rest of the study population in a 
1:1 ratio, matched for age, sex, GP, and 
calendar time. 
Outcomes and follow-up
The primary diagnosis in the first episode (a 
single period of care under one consultant 
team) within a spell (a patient’s entire stay 
in hospital) in the HES was examined; this 
was considered to be the main reason 
why a patient required hospital admission.30 
Outcomes of this study were hospitalisations 
for 10 common conditions as the primary 
admission diagnosis: heart failure; 
urinary tract infection; pneumonia; AKI; 
myocardial infarction; cerebral infarction; 
gastrointestinal bleeding; hip fracture; 
venous thromboembolism; and intracranial 
bleeding, defined using ICD-10 codes 
(Appendix 1). In this study, the researchers 
focused on the first hospitalisation for each 
condition after cohort entry.
For each outcome, a patient was followed 
up until the first hospitalisation for that 
outcome or the end of eligibility (initiation of 
renal replacement therapy, death, change 
of GP, last data collection from the GP, 
or 31 March 2014), meaning that every 
patient could develop more than one of the 
outcomes. In addition, individuals selected 
in the comparison group (patients without 
known CKD) could be found to have CKD 
later; in this situation they were censored 
at the time of satisfying the CKD definition 
because they were already included in the 
CKD group from that point forward. 
Covariates
In addition to the matched factors, the 
researchers accounted for potential 
confounders in the association between 
CKD and cause-specific hospitalisation: 
ethnicity; socioeconomic status; smoking 
status; body mass index (BMI); and 17 
comorbidities (asthma, atrial fibrillation, 
cancer, chronic obstructive pulmonary 
disease [COPD], coronary heart disease, 
dementia, depression, diabetes mellitus, 
epilepsy, heart failure, hypertension, 
hypothyroidism, severe mental illness, 
osteoporosis, peripheral arterial disease, 
rheumatoid arthritis, and stroke and 
transient ischaemic attack [TIA]).
Patients with no record of ethnicity were 
classed as white, based on previous studies 
in UK primary care.35,36 Socioeconomic 
status was assigned by quintile at an 
individual level using the Index of Multiple 
How this fits in
Although chronic kidney disease (CKD) is 
associated with a wide range of adverse 
outcomes, more strongly associated 
conditions with hospital admission 
among patients with CKD are unknown. 
This study is the first to examine the 
association between CKD and common 
reasons for hospital admission in a 
systematic way and highlights the high 
burden of hospitalisation due to heart 
failure, infection, and acute kidney injury 
among patients with CKD compared with 
the general population. These findings 
suggest that, aside from prevention of end-
stage kidney disease, there are important 
high-priority outcomes that warrant 
identification of CKD in primary care and 
improved preventive care of patients with 
CKD in the community.
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Deprivation as a composite area-level 
marker of deprivation.37 Smoking status and 
BMI were assigned using the data recorded 
closest to the cohort entry. The definitions 
of hypertension and diabetes were based 
on relevant diagnosis codes recorded 
before the cohort entry or prescription 
(antihypertensive and antidiabetic drugs, 
respectively) in the past 1 year prior to 
the cohort entry. Other comorbidities were 
based on relevant diagnosis codes recorded 
before the cohort entry.
Statistical analysis
The baseline characteristics of matched 
patients with and without CKD were 
compared using χ2 tests. Incidence rates 
of each outcome in matched patients 
with and without CKD, respectively, were 
estimated and a difference of incidence 
rates between the groups was calculated. 
Multivariate Cox regression analyses 
for each outcome were then conducted, 
stratified by matched set to account for the 
matching on age, sex, GP, and calendar 
time (Model 1). Further adjustments were 
made for ethnicity, socioeconomic and 
smoking status, BMI, and diabetes mellitus 
(Model 2). Instead of excluding patients with 
a missing status of smoking or BMI from 
the analysis, an additional absent category 
was included for these patients to maintain 
the matched set between patients with and 
without CKD. Subsequently, adjustments 
for comorbidities not directly related to 
CKD (asthma, cancer, COPD, dementia, 
depression, epilepsy, hypothyroidism, 
severe mental illness, osteoporosis, and 
rheumatoid arthritis)38 (Model 3) were made, 
and also for comorbidities, which may occur 
concordantly with CKD (atrial fibrillation, 
coronary heart disease, heart failure, 
hypertension, peripheral arterial disease, 
stroke and TIA)38 (Model 4). A fully adjusted 
sub-hazard ratio for each outcome using 
the Fine and Gray model was estimated 
to account for potential competing risk 
(initiation of renal replacement therapy and 
death) between patients with and without 
CKD. Because of the computational burden 
related to size of the dataset, this competing 
risk analysis was conducted using a 20% 
random sample of the whole dataset. All 
the statistical analyses were carried out 
using STATA (version 14).
Subgroup analyses
Several subgroup analyses were conducted. 
First, as previous studies suggested that the 
impact of CKD on outcomes may change 
with age,39,40 all the analyses were repeated 
by classifying the study population into two 
age groups; ≥75 and <75 years. Second, to 
examine the extent of graded association 
between CKD stage and cause-specific 
hospitalisation, the researchers conducted 
Cox regression analyses by dividing patients 
with CKD according to baseline CKD 
stage: 3a (eGFR 45–59 mL/ min/1.73 m2), 
3b (eGFR 30–44 mL/min/1.73 m2), and 4 
or 5 (eGFR <30 mL/min/1.73 m2).32 Third, 
to see the impact of CKD on cause-
specific hospitalisation among patients 
with no history of cardiovascular disease, 
patients with either diagnosis of atrial 
fibrillation, coronary heart disease, heart 
failure, peripheral arterial disease, and 
stroke and TIA at the cohort entry were 
excluded, and Cox regression analyses were 
performed by CKD stage. In the second 
and third subgroup analyses where the 
matched nature between patients with and 
without CKD was no longer maintained, 
adjustments for age, sex, and financial year 
were made, and robust standard errors 
to allow for clustering by GP were used, 
instead of stratification by matched set in 
the Cox regression models. 
RESULTS
Among 4 070 806 eligible patients not 
requiring renal replacement therapy (mean 
age 42.7 [SD 18.8] years, male 48.8%), the 
researchers identified 264 628 (6.5%) patients 
with CKD (mean age 76.4 [SD 10.0] years, 
male 38.7%) (Figure 1). Of those with CKD, 
242 349 (92%) were matched with patients 
without CKD (mean age 75.4 [SD 9.7] years, 
male 39.3%). Unmatched 22 279 patients 
with CKD (8% of those with CKD) were older 
and more likely to be female (mean age 87.9 
[SD 5.4] years, male 31.5%). Patients with 
CKD were more likely to have a deprived 
CKD = chronic kidney disease. CPRD = Clinical Practice Research Datalink. HES = Hospital Episode
Statistics.
All adults in HES-linked CPRD between 1 April 2004 and 31 March 2014
N = 4 073 639
Patients on renal replacement therapy
N = 2833
All adults not on renal replacement therapy
N = 4 070 806
Patients with CKD
N = 264 628 (6.5%)
Patients with CKD
(matching available)
N = 242 349 (92%)
Patients 
without CKD 
N = 242 349
Matched for 
 - age
 - sex
 - GP
 - calendar time
Figure 1. Selection method of matched patients with 
and without CKD from the general population.
CKD = chronic kidney disease. CPRD = Clinical 
Practice Research Datalink. HES = Hospital Episode 
Statistics.
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socioeconomic status, be ex-smokers, 
and overweight, with a larger number of 
comorbidities (Table 1). Total length of follow-
up, if not censored for each cause-specific 
hospitalisation, was 2.0 million person-years 
(mean 4.2 [SD 2.9] years/person).
Among the 10 cause-specific 
hospitalisations, the largest incidence rate 
difference was seen for heart failure at 
6.6/1000 person-years (9.7/1000 versus 
3.1/1000 person-years in matched patients 
with and without CKD, respectively), followed 
by urinary tract infection at 5.2/1000 person-
years, pneumonia at 4.4/1000 person-years, 
and AKI at 4.1/1000 person-years (Table 
2). Hip fracture, venous thromboembolism, 
and intracranial bleeding marked relatively 
small differences of incidence rates 
between matched patients with and without 
CKD.
The relative risk was consistently highest 
for AKI, followed by heart failure in all the 
models, though the rank order of other 
outcomes varied depending on the extent of 
adjustment for confounding factors (Table 3). 
The age- and sex-adjusted hazard ratio for 
AKI in Model 1 was 6.49, 95% CI = 5.99 to 
7.03, followed by heart failure with 3.28, 95% 
CI = 3.15 to 3.41. The fully adjusted hazard 
ratio for AKI in Model 4 was 4.90, 95% 
CI = 4.47 to 5.38, followed by heart failure 
with 1.66, 95% CI = 1.59 to 1.75. Intracranial 
bleeding and hip fracture marked relatively 
small fully adjusted hazard ratios. Results 
of competing risk analyses were generally 
similar to or slightly higher than those 
estimated in the main analysis. Likewise, 
AKI and heart failure exhibited higher sub-
hazard ratios than others.
In subgroup analysis by age, the incidence 
rate difference between matched patients 
with and without CKD tended to be larger 
and the relative risk tended to be smaller 
in the older subgroup (≥75 years of age) 
than the younger subgroup (<75 years 
of age) for almost all the cause-specific 
hospitalisations (Table 4). However, the rank 
order in the size of absolute rate difference 
and relative risk was almost the same as 
the main results in each age group. 
Of 242 349 matched patients with CKD, 
71.2% (n = 172 555) , 22.9% (n = 55 500), and 
5.9%, (n = 14 294) patients were in stage 3a, 
3b, and 4 or 5, respectively. Patients tended 
to be older and sicker as kidney function 
declined. Details of baseline characteristics 
of patients with different stages of CKD 
are available from the authors. There were 
graded associations between CKD stage 
and all the cause-specific hospitalisations, 
but the strength of the association was 
larger for AKI and heart failure (Figure 2 and 
Appendix 2). 
Among patients with no history of 
cardiovascular disease, the strength of the 
association was similar to that in the main 
analysis for all the studied cause-specific 
hospitalisations (Appendix 3).
Table 1. Baseline characteristics of matched patients with and without 
chronic kidney disease
 Patients without CKD Patients with CKD 
 N = 242 349 N = 242 349  
Characteristic n (%) n (%) P-value
Age, years   1.000 
 <55 6845 (2.8) 6845 (2.8)  
 55–64 23 556 (9.7) 23 556 (9.7)  
 65–74 71 112 (29.3) 71 112 (29.3)  
 75–84 102 594 (42.3) 102 594 (42.3)  
 ≥85 38 242 (15.8) 38 242 (15.8) 
Sex (male) 95 318 (39.3) 95 318 (39.3) 1.000
Ethnicity   <0.001 
 White/not recorded 238 533 (98.4) 238 138 (98.3)  
 South Asian  1796 (0.7) 2317 (1.0)  
 Black 1156 (0.5) 1060 (0.4)  
 Other  864 (0.4) 834 (0.3) 
Socioeconomic status   <0.001 
 1 (least deprived) 56 800 (23.4) 53 034 (21.9)  
 2 61 647 (25.4) 60 501 (25.0)  
 3 50 466 (20.8) 50 709 (20.9)  
 4 42 221 (17.4) 44 692 (18.4)  
 5 (most deprived) 31 215 (12.9) 33 413 (13.8) 
Smoking status   <0.001 
 Non-smoker 92 363 (38.1) 80 721 (33.3)  
 Ex-smoker 107 737 (44.5) 131 510 (54.3)  
 Current smoker 36 338 (15.0) 29 243 (12.1)  
 Missing 5911 (2.4) 875 (0.4) 
Body mass index, kg/m2   <0.001 
 <18.5 6638 (2.7) 4562 (1.9)  
 18.5–25 85 473 (35.3) 70 102 (28.9)  
 ≥25 80 458 (33.2) 88 083 (36.4)  
 ≥30 40 326 (16.6) 63 183 (26.1)  
 Missing 29 454 (12.2) 16 419 (6.8) 
Comorbidities    
 Asthma 28 002 (11.6) 31 271 (12.9) <0.001 
 Atrial fibrillation 15 448 (6.4) 29 515 (12.2) <0.001 
 Cancer 47 431 (19.6) 54 450 (22.5) <0.001 
 Chronic obstructive pulmonary disease 14 996 (6.2) 18 229 (7.5) <0.001 
 Coronary heart disease 27 961 (11.5) 54 049 (22.3) <0.001 
 Dementia 8954 (3.7) 7345 (3.0) <0.001 
 Depression 38 490 (15.9) 46 233 (19.1) <0.001 
 Diabetes mellitus 24 372 (10.1) 52 927 (21.8) <0.001 
 Epilepsy 3972 (1.6) 3682 (1.5) 0.001 
 Heart failure 7581 (3.1) 23 774 (9.8) <0.001 
 Hypertension 128 828 (53.2) 203 963 (84.2) <0.001 
 Hypothyroidism 17 443 (7.2) 29 318 (12.1) <0.001 
 Severe mental illness 3522 (1.5) 4890 (2.0) <0.001 
 Osteoporosis 16 469 (6.8) 16 610 (6.9) 0.422 
 Peripheral arterial disease 7481 (3.1) 14 815 (6.1) <0.001 
 Rheumatoid arthritis 4270 (1.8) 6031 (2.5) <0.001 
 Stroke and transient ischaemic attack 12 243 (5.1) 19 982 (8.3) <0.001
CKD = chronic kidney disease
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DISCUSSION
Summary
In this population-based cohort study, 
among people with CKD (stages 3–5) 
large absolute increases in rates of 
hospitalisations due to heart failure, infection 
(urinary tract infection and pneumonia), 
and AKI were found, compared with age- 
and sex-matched controls without known 
CKD from the same GP. Before and after 
adjustment for confounding factors, the 
relative risk of hospitalisation was highest 
for AKI, followed by heart failure. Results 
were similar in subgroup analyses by age 
and CKD stage, and among patients with 
no history of cardiovascular disease. The 
vast majority of patients in the cohort had 
CKD stage 3a or 3b so would be primarily 
diagnosed and managed in primary care, 
making these findings useful and relevant 
Table 2. Difference in the incidence rate of cause-specific hospitalisation between matched patients with 
and without chronic kidney disease by rank order of rate difference
 Number of outcome, n Incidence rate per 1000 person-years (95%CI)
 Patients with CKD Patients without CKD Patients Patients Rate 
Cause of hospitalisation (N = 242 349) (N = 242 349) with CKD without CKD difference
Heart failure 10 394 2955 9.7 (9.5 to 9.9) 3.1 (3.0 to 3.2) 6.6 (6.4 to 6.8)
Urinary tract infection 14 266 7654 13.1 (12.9 to 13.3) 7.9 (7.7 to 8.1) 5.2 (4.9 to 5.5)
Pneumonia 13 483 7803 12.6 (12.4 to 12.8) 8.2 (8.0 to 8.4) 4.4 (4.1 to 4.7)
Acute kidney injury 5257 787 4.9 (4.7 to 5.0) 0.8 (0.8 to 0.9) 4.1 (3.9 to 4.2)
Myocardial infarction 7418 3590 6.9 (6.8 to 7.1) 3.8 (3.6 to 3.9) 3.2 (3.0 to 3.4)
Cerebral infarction 6142 3335 5.7 (5.6 to 5.8) 3.5 (3.4 to 3.6) 2.2 (2.0 to 2.4)
Gastrointestinal bleeding 5492 3048 5.1 (5.0 to 5.2) 3.2 (3.1 to 3.3) 1.9 (1.7 to 2.1)
Hip fracture  9336 6751 8.7 (8.6 to 8.9) 7.1 (7.0 to 7.3) 1.6 (1.4 to 1.9)
Venous thromboembolism 3299 1882 3.1 (3.0 to 3.2) 2.0 (1.9 to 2.1) 1.1 (1.0 to 1.2)
Intracranial bleeding 2144 1427 2.0 (1.9 to 2.1) 1.5 (1.4 to 1.6) 0.5 (0.4 to 0.6)
CKD = chronic kidney disease.
Table 3. Relative risk for cause-specific hospitalisation between matched patients with and without chronic 
kidney disease by rank order of fully adjusted hazard ratio
 Adjusted hazard ratio (95% CI)a Fully adjusted
    Model 4 sub-hazard 
Cause of hospitalisation Model 1 Model 2 Model 3 (fully adjusted model) ratio (95% CI)b
Acute kidney injury 6.49 (5.99 to 7.03) 5.95 (5.46 to 6.47) 5.82 (5.34 to 6.35) 4.90 (4.47 to 5.38) 4.98 (4.23 to 5.87)
Heart failure 3.28 (3.15 to 3.41) 2.84 (2.73 to 2.96) 2.79 (2.67 to 2.90) 1.66 (1.59 to 1.75) 2.07 (1.88 to 2.28)
Venous thromboembolism 1.60 (1.53 to 1.68) 1.57 (1.49 to 1.65) 1.54 (1.46 to 1.62) 1.55 (1.46 to 1.64) 1.57 (1.37 to 1.80)
Myocardial infarction 1.84 (1.78 to 1.91) 1.70 (1.64 to 1.76) 1.67 (1.61 to 1.73) 1.40 (1.34 to 1.46) 1.53 (1.38 to 1.69)
Urinary tract infection 1.62 (1.58 to 1.67) 1.53 (1.49 to 1.57) 1.50 (1.46 to 1.54) 1.39 (1.35 to 1.43) 1.59 (1.50 to 1.69)
Gastrointestinal bleeding 1.59 (1.53 to 1.66) 1.55 (1.49 to 1.62) 1.52 (1.46 to 1.58) 1.34 (1.28 to 1.40) 1.55 (1.41 to 1.72)
Cerebral infarction 1.55 (1.49 to 1.61) 1.51 (1.46 to 1.58) 1.51 (1.45 to 1.58) 1.27 (1.22 to 1.33) 1.45 (1.30 to 1.60)
Pneumonia 1.47 (1.43 to 1.51) 1.46 (1.42 to 1.50) 1.44 (1.40 to 1.49) 1.24 (1.20 to 1.29) 1.49 (1.39 to 1.59)
Hip fracture  1.11 (1.08 to 1.14) 1.18 (1.14 to 1.21) 1.17 (1.13 to 1.21) 1.11 (1.07 to 1.15) 1.37 (1.27 to 1.48)
Intracranial bleeding 1.28 (1.21 to 1.36) 1.30 (1.22 to 1.38) 1.29 (1.21 to 1.38) 1.10 (1.02 to 1.19) 1.30 (1.11 to 1.52)
aAdjusted hazard ratio (patients with chronic kidney disease versus those without) was estimated in the following Cox regression models: Model 1: Stratified by matched set to 
account for the matching on age, sex, general practice, and calendar time. Model 2: Model 1 + adjusted by ethnicity, socioeconomic and smoking status, body mass index, and 
diabetes mellitus. Model 3: Model 2 + adjusted by comorbidities not directly related to chronic kidney disease (asthma, cancer, chronic obstructive pulmonary disease, dementia, 
depression, epilepsy, hypothyroidism, severe mental illness, osteoporosis, and rheumatoid arthritis). Model 4: Model 3 + adjusted by all the other comorbidities that may occur 
concordantly with chronic kidney disease (atrial fibrillation, coronary heart disease, heart failure, hypertension, peripheral arterial disease, and stroke and transient ischaemic 
attack). bFully adjusted sub-hazard ratio was estimated by the model of Fine and Gray to account for competing risk (initiation of renal replacement therapy and death) between 
patients with and without chronic kidney disease, using a 20% random sample of the whole dataset.
5  British Journal of General Practice, Online First 2018
for routine clinical care. 
Strengths and limitations
A major strength of this study was that it 
compared those with CKD to those without, 
sampled from the general population. A 
comparison was possible because over 98% 
of the UK population are registered with 
a primary care practice. The study results 
obtained from HES-linked CPRD are likely 
to be generalisable to the entire English 
population.29
Limitations of the study include, first, that 
patients who had never had kidney function 
tested were kept in the denominator in order 
for the comparison group to be representative 
of the general population. Currently in the UK, 
serum creatinine testing is recommended 
and incentivised for people with known CKD 
risk factors.3,41 If some patients had been 
misclassified with unmeasured CKD to 
the matched comparison group, the true 
association between CKD and each cause-
specific hospitalisation may have been 
underestimated. However, the researchers 
have recently shown that the prevalence of 
patients with an eGFR <60 mL/min/1.73 m2 
identified in CPRD was similar to that in 
a population-representative survey (Health 
Survey for England),42 suggesting that 
most of these patients are captured with 
the current testing strategy in UK primary 
care, and people without creatinine tests are 
unlikely to have CKD stages 3–5.43 If healthy 
people without creatinine measurement 
were excluded from the denominator, severe 
selection bias would arise and estimated 
absolute risk differences between patients 
with and without CKD would not be 
informative.44
Second, relative risks between CKD status 
(stage) and cause-specific hospitalisation 
depend partly on the extent of adjustment 
for potential confounders. Previous studies 
on the association between CKD and 
outcomes adjusted for disease diagnoses 
(based on patient charts, administrative 
claim data, or questionnaire answered by 
patients), physiological measurements, 
blood test results, or prescriptions to 
various degrees conclude that CKD is 
‘independently’ associated with their studied 
outcomes.15–28 However, the possibility of 
residual confounding inevitably remains. 
In this study, adjustments were made for 
important patient characteristics as well as 
diagnoses of 17 comorbidities. Recording 
of these conditions has been incentivised 
since the introduction of the UK Quality and 
Outcomes Framework in 2004,3 resulting 
in marked improvements in data quality.29 
Further, differences of disease diagnosis 
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and coding among different GPs and over 
time was minimised by matching on GP 
and calendar time between patients with 
and without CKD. Therefore, the authors 
believe that the best available approach 
of adjustment for confounding was used 
to compare the relative risks between 
CKD and different types of cause-specific 
hospitalisations. 
Finally, although the researchers 
acknowledge that proteinuria is an 
important outcome prediction marker,32 
the authors of this study were not able to 
stratify patients by the level of proteinuria or 
quantify the association between proteinuria 
and cause-specific hospitalisation. This 
is because proteinuria was infrequently 
checked in CPRD: testing rate of proteinuria 
(including dipstick testing) in the year prior 
to cohort entry was 23.2% (56 431 out of 
242 349 patients) in the CKD group and 
12.6% (30 616 out of 242 349 patients) in 
the comparison group. It would not be 
appropriate to assume that people without 
urine testing did not have proteinuria. 
Comparison with existing literature
There have been several studies 
demonstrating an association between 
CKD and increased risk of all-cause 
hospitalisations.9,11–13 However, these 
studies did not clearly differentiate causes 
of hospitalisation, and therefore it remained 
unclear why this is the case. Meanwhile, 
a previous study recruiting patients with 
elevated serum creatinine suggested that 
cardiovascular disease and hypertension 
were the most common reason for 
hospitalisation, followed by infection.45 
However, in the absence of a comparison 
group without CKD, it remained unclear 
whether these hospitalisations were specific 
to CKD or common in the community 
regardless of CKD status.
As well as a known association between 
CKD and AKI,46 a number of studies have 
reported positive associations between CKD 
and incidence of non-renal conditions.15–28 
Many of these studies used hospital 
admission for their outcome definitions. 
However, these individual studies did 
not allow a comparison of the impact of 
CKD across different outcomes, because 
absolute and relative risk related to 
CKD were estimated in different study 
populations and with various degrees of 
statistical adjustment for confounders. To 
the authors’ knowledge, the current study is 
the first to quantify the association between 
CKD status (stage) and cause-specific 
hospitalisation.
Implications for research and practice 
After the classification of CKD, and the 
implementation of testing and registering 
of patients with CKD through the Quality 
and Outcomes Framework for CKD in 
2006,3 some have questioned the benefits 
of this approach.47 Patients with mild CKD 
may be perceived to have normal kidney 
ageing, or with multiple morbidities putting 
them at increased risk for many adverse 
outcomes. This study was planned to clarify 
the adverse outcomes (that were likely to 
be causally related to kidney function) that 
were more common and specific among 
patients with CKD in primary care, enabling 
the possibility of better-targeted care.
The adjusted hazard ratios were small 
for most of the outcomes in patients with 
CKD stage 3a (Figure 2), except for AKI 
with a threefold increase in the adjusted 
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Figure 2. Fully adjusted hazard ratio for cause-specific 
hospitalisation by chronic kidney disease stage 
estimated using Cox regression models, adjusted by 
age, sex, financial year, ethnicity, socioeconomic and 
smoking status, body mass index, and comorbidities 
(asthma, atrial fibrillation, cancer, chronic obstructive 
pulmonary disease, coronary heart disease, dementia, 
depression, diabetes mellitus, epilepsy, heart failure, 
hypertension, hypothyroidism, severe mental illness, 
osteoporosis, peripheral arterial disease, rheumatoid 
arthritis, and stroke and transient ischaemic attack) 
and clustered by general practice using robust 
standard errors (corresponding to Appendix 2). 
CKD = chronic kidney disease.
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hazard ratio for hospitalisations; and nearly 
one and a half-fold increase for heart 
failure. These results highlight the marked 
increase in risk of AKI and heart failure for 
patients with only mild reductions in kidney 
function, with implications for targeted 
prevention and medication management; 
for example, minimisation of non-steroidal 
antiinflammatory drug use. 
Both absolute and relative risk provide 
important information about the impact of 
CKD on cause-specific hospitalisation.40,48 
The relative risk (adjusted hazard ratio) is a 
measure of the strength of the association 
between CKD and each cause-specific 
hospitalisation, after taking into account 
a range of comorbidities. Meanwhile, the 
absolute risk difference reflects the relative 
risk and the baseline frequency of each 
outcome in the community, indicating the 
actual burden of each condition among 
patients with CKD as compared with 
the general population. For example, 
infections, such as urinary tract infection 
and pneumonia, showed intermediate 
relative risks among the studied outcomes, 
but their absolute risk differences between 
patients with and without CKD were large 
because hospitalisations for infection were 
common in the general population. The 
absolute risk difference is also useful for 
understanding the potential benefits of 
preventive strategies. For example, Table 
2 shows that 9.7 and 3.1 patients per 1000 
patients with and without CKD (stages 3–5), 
respectively, were hospitalised for heart 
failure in a year, meaning that, of 1000 
people with CKD, up to 6.6 could benefit 
from targeted heart failure admission 
prevention. This would translate to three 
people per year in a GP practice of 7400 
patients (average number of patients per 
practice)49 where 6.5% have CKD. Further 
estimates for all outcomes are available 
from the authors. However, these numbers 
are likely to be underestimates of the overall 
benefits because follow-up of patients at 
the time of first hospitalisation after cohort 
entry was stopped and, therefore, did not 
account for repeated admissions. 
Patients with CKD, even without renal 
replacement therapy, are known to incur 
substantive healthcare costs through 
frequent hospitalisations.10 Based 
on results from this study, a focus on 
strategies to reduce hospitalisations for 
heart failure, such as education on dietary 
salt restriction50 and improved medication 
adherence,51 could help to minimise the 
difference in the overall hospitalisation rate 
between patients with and without CKD. 
Similarly, a proportion of hospitalisations 
due to infections may be preventable 
through prompt antibiotic treatment and 
improvement of vaccination coverage 
among patients with CKD.52 Pneumococcal 
vaccination has been underutilised in 
patients with CKD (stages 4 and 5) to date.53
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Appendix 2. Fully adjusted hazard ratio for cause-specific hospitalisation by chronic kidney disease stage 
 Fully adjusted hazard ratio (95% CI)a by CKD stage
 Patients with CKD (N = 242 349)
 Patients without CKD CKD stage 3a CKD stage 3b CKD stage 4 or 5 
Cause of hospitalisation (N = 242 349) (N = 172 555) (N = 55 500) (N = 14 294)
Acute kidney injury 1b 2.94 (2.69 to 3.20) 7.03 (6.39 to 7.73) 20.22 (18.14 to 22.54)
Heart failure 1b 1.43 (1.37 to 1.50) 2.13 (2.02 to 2.24) 3.29 (3.06 to 3.54)
Venous thromboembolism 1b 1.36 (1.28 to 1.45) 1.68 (1.53 to 1.83) 2.09 (1.78 to 2.46)
Myocardial infarction 1b 1.25 (1.19 to 1.31) 1.58 (1.48 to 1.67) 2.18 (1.99 to 2.38)
Urinary tract infection 1b 1.23 (1.19 to 1.27) 1.61 (1.55 to 1.68) 2.40 (2.25 to 2.57)
Gastrointestinal bleeding 1b 1.24 (1.18 to 1.31) 1.53 (1.43 to 1.64) 2.12 (1.90 to 2.37)
Cerebral infarction 1b 1.21 (1.15 to 1.27) 1.39 (1.31 to 1.48) 1.58 (1.40 to 1.78)
Pneumonia 1b 1.11 (1.07 to 1.15) 1.50 (1.44 to 1.57) 1.97 (1.84 to 2.11)
Hip fracture  1b 1.04 (1.00 to 1.08) 1.29 (1.24 to 1.36) 1.72 (1.59 to 1.85)
Intracranial bleeding  1b 1.08 (1.00 to 1.16) 1.31 (1.19 to 1.45) 1.28 (1.03 to 1.60)
aFully adjusted hazard ratio was estimated using Cox regression models, adjusted by age, sex, financial year, ethnicity, socioeconomic and smoking status, body mass index, and 
comorbidities (asthma, atrial fibrillation, cancer, chronic obstructive pulmonary disease, coronary heart disease, dementia, depression, diabetes mellitus, epilepsy, heart failure, 
hypertension, hypothyroidism, severe mental illness, osteoporosis, peripheral arterial disease, rheumatoid arthritis, and stroke and transient ischaemic attack) and clustered by 
general practice using robust standard errors. bReference. CKD = chronic kidney disease.
Appendix 1. List of International Classification of Diseases 10th Revision codes used to identify cause-specific 
hospitalisations
Outcome International Classification of Diseases 10th Revision codes
Myocardial infarction I21, I22, I23
Heart failure I50
Cerebral infarction I63
Pneumonia B01.2, B05.2, B20.6, B25.0, J10.0, J11.0, J12, J13, J14, J15, J16, J17, J18, J85.1, U04
Urinary tract infection N10, N12, N13.6, N15.1, N15.9, N30.0, N30.8, N30.9, N39.0
Gastrointestinal bleeding I85.0, K22.6, K25.0, K25.1, K25.2, K25.4, K25.5, K25.6, K26.0, K26.1, K26.2, K26.4, K26.5, K26.6, K27.0, K27.1, K27.2, K27.4, K27.5, K27.6,  
 K28.0, K28.1, K28.2, K28.4, K28.5, K28.6, K29.0, K92.0, K92.1, K92.2
Intracranial bleeding I60, I61, I62, S06.5, S06.6
Venous thromboembolism I80.1, I80.2, I80.3, I81, I82.2, I82.3, I82.8, I82.9, I26
Hip fracture  S72
Acute kidney injury  N17
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Appendix 3. Fully adjusted hazard ratio for cause-specific hospitalisation by chronic kidney disease stage 
among patients with no history of cardiovascular disease
 Fully adjusted hazard ratio (95% CI)a by CKD stage
   Patients with CKD (N = 143 715)
 Patients without CKD CKD stage 3a CKD stage 3b CKD stage 4 or 5 
Cause of hospitalisation (N = 187 322) (N = 107 803) (N = 29 085) (N = 6827)
Acute kidney injury 1b  2.65 (2.39 to 2.93) 7.09 (6.29 to 8.00) 24.20 (21.22 to 27.61)
Heart failure 1b  1.25 (1.17 to 1.35) 1.95 (1.78 to 2.14) 3.41 (2.96 to 3.94)
Venous thromboembolism 1b  1.43 (1.33 to 1.54) 1.66 (1.48 to 1.85) 2.23 (1.80 to 2.76)
Myocardial infarction 1b  1.25 (1.16 to 1.34) 1.61 (1.47 to 1.76) 2.24 (1.92 to 2.60)
Urinary tract infection 1b  1.27 (1.21 to 1.33) 1.75 (1.66 to 1.85) 3.15 (2.87 to 3.46)
Gastrointestinal bleeding 1b  1.29 (1.20 to 1.38) 1.56 (1.41 to 1.72) 2.13 (1.79 to 2.54)
Cerebral infarction 1b  1.19 (1.11 to 1.28) 1.45 (1.33 to 1.58) 1.56 (1.31 to 1.86)
Pneumonia 1b  1.14 (1.09 to 1.19) 1.56 (1.47 to 1.65) 2.33 (2.11 to 2.58)
Hip fracture  1b  1.03 (0.98 to 1.08) 1.27 (1.19 to 1.35) 1.69 (1.50 to 1.91)
Intracranial bleeding  1b  1.10 (0.99 to 1.21) 1.42 (1.24 to 1.63) 1.35 (0.98 to 1.85)
aAfter excluding patients with a history of cardiovascular disease (atrial fibrillation, coronary heart disease, heart failure, peripheral arterial disease, or stroke and transient 
ischaemic attack) from the matched patients with and without CKD, fully adjusted hazard ratios were estimated using Cox regression models, adjusted by age, sex, financial year, 
ethnicity, socioeconomic and smoking status, body mass index, and comorbidities (asthma, cancer, chronic obstructive pulmonary disease, dementia, depression, diabetes mellitus, 
epilepsy, hypertension, hypothyroidism, severe mental illness, osteoporosis, and rheumatoid arthritis) and clustered by general practice using robust standard errors. bReference. 
CKD = chronic kidney disease.
British Journal of General Practice, Online First 2018  12 
